{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T11:29:26Z","timestamp":1690284566670},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00347-016-0308-7","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T02:38:55Z","timestamp":1467254335000},"page":"49-56","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Visusprognose bei der Anti-\ufeffVEGF-\ufeffTherapie der AMD"],"prefix":"10.1007","volume":"114","author":[{"given":"B.","family":"Book","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Heimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gutfleisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Spital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pauleikhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"308_CR1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"308_CR2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"key":"308_CR3","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) VIEW 1 and VIEW 2 study groups (2012) Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"308_CR4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193\u2013201","journal-title":"Ophthalmology"},{"key":"308_CR5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMicm1005605","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908","journal-title":"N Engl J Med"},{"key":"308_CR6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, 3rd Ferris FL (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","journal-title":"Ophthalmology"},{"key":"308_CR7","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399\u20131411","journal-title":"Ophthalmology"},{"issue":"9900","key":"308_CR8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downers SM, Lotery AJ, Culliford LA, Reeves BC, IVAN study investigators (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2\u2011year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258\u20131267","journal-title":"Lancet"},{"issue":"4","key":"308_CR9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118(4):663\u2013671","journal-title":"Ophthalmology"},{"issue":"8","key":"308_CR10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","volume":"132","author":"GS Ying","year":"2014","unstructured":"Ying GS, Kim BJ, Maguire MG, Huang J, Daniel E, Jaffe GJ, Grunwald JE, Blinder KJ, Flaxel CJ, Rahhel F, Regillo C, Martin DF, CATT Research Group (2014) Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 132(8):915\u2013921","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"308_CR11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00417-010-1524-5","volume":"249","author":"B Heimes","year":"2011","unstructured":"Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Dietzel M, Pauleikhoff D (2011) Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249(5):639\u2013644","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"308_CR12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1136\/bjo.2010.201129","volume":"95","author":"R Hoerster","year":"2011","unstructured":"Hoerster R, Muether PS, Hermann MM, Koch K, Kirchhof B, Fauser S (2011) Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. Br J Ophthalmol 95(10):1424\u20131426","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"308_CR13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00417-011-1636-6","volume":"249","author":"H Gerding","year":"2011","unstructured":"Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M (2011) Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 249(5):653\u2013662","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"308_CR14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0032-1328113","volume":"230","author":"Retinologischen Gesellschaft","year":"2013","unstructured":"Retinologische Gesellschaft, Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (2013) Die Anti-VEGF-Therapie bei der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration: therapeutische Strategien \u2013 Status Dezember 2012. Klin Monbl Augenheilkd 230:170\u2013177 (Aktuelle Stellungnahme)","journal-title":"Klin Monbl Augenheilkd"},{"key":"308_CR15","first-page":"405","volume":"110","author":"Retinologischen Gesellschaft","year":"2013","unstructured":"Retinologische Gesellschaft, Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (2013) Die Anti-VEGF-Therapie bei der neovaskul\u00e4ren alterabh\u00e4ngigen Makuladegeneration: Therapeutische Strategien \u2013 Status Dezember 2012. Ophthalmologe 110:405\u2013414 (Aktuelle Stellungnahme)","journal-title":"Ophthalmologe"},{"key":"308_CR16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0034-1396162","volume":"232","author":"Retinologischen Gesellschaft","year":"2015","unstructured":"Retinologische Gesellschaft, Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (2015) Die Anti-VEGF-Therapie bei der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration: therapeutische Strategien \u2013 Status Dezember 2014. Klin Monbl Augenheilkd 232:202\u2013210 (Aktuelle Stellungnahme)","journal-title":"Klin Monbl Augenheilkd"},{"key":"308_CR17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00347-014-3222-x","volume":"112","author":"Retinologischen Gesellschaft","year":"2015","unstructured":"Retinologische Gesellschaft, Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (2015) Die Anti-VEGF-Therapie bei der neovaskul\u00e4ren alterabh\u00e4ngigen Makuladegeneration: Therapeutische Strategien \u2013 Status Dezember 2014. Ophthalmologe 112:237\u2013247 (Aktuelle Stellungnahme)","journal-title":"Ophthalmologe"},{"issue":"2","key":"308_CR18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00347-010-2210-z","volume":"108","author":"B Heimes","year":"2011","unstructured":"Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Pauleikhoff D (2011) Anti-VEGF Therapie der exsudativen AMD: Prognostische Faktoren f\u00fcr den Therapieerfolg. Ophthalmologe 108(2):124\u2013131","journal-title":"Ophthalmologe"},{"issue":"1","key":"308_CR19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ajo.2012.01.030","volume":"154","author":"YM Kim","year":"2012","unstructured":"Kim YM, Kim JH, Koh HJ (2012) Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol 154(1):164\u2013173","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"308_CR20","first-page":"62","volume":"6","author":"J Chhablani","year":"2013","unstructured":"Chhablani J, Kim JS, Freeman WR, Kozak I, Wang HY, Cheng L (2013) Predictors of visual outcome in eyes with choroidal neovascularization secondary to age related macular degeneration treated with intravitreal bevacizumab monotherapy. Int J Ophthalmol 6(1):62\u201366","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"308_CR21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","volume":"120","author":"GS Ying","year":"2013","unstructured":"Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF (2013) Comparison of age-related macular degeneration treatments trials research group. baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120(1):122\u2013129","journal-title":"Ophthalmology"},{"issue":"2","key":"308_CR22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00417-012-2034-4","volume":"251","author":"A Oishi","year":"2013","unstructured":"Oishi A, Shimozono M, Mandai M, Hata M, Nishida A, Kurimoto Y (2013) Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251(2):435\u2013440","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"308_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pone.0091227","volume":"9","author":"Y Subhi","year":"2014","unstructured":"Subhi Y, Henningsen GO, Larsen CT, Sorensen MS, Sorensen TL (2014) Foveal morphology affects self-perceived visual function and treatment response in neovascular age-related macular degeneration: a cohort study. PLoS ONE 9:3","journal-title":"PLoS ONE"},{"issue":"5","key":"308_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3341\/kjo.2014.28.5.386","volume":"28","author":"YH Kwon","year":"2014","unstructured":"Kwon YH, Lee DK, Kim HE, Kwon OW (2014) Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration. Korean J Ophthalmol 28(5):386\u2013392","journal-title":"Korean J Ophthalmol"},{"issue":"12","key":"308_CR25","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","volume":"122","author":"GS Ying","year":"2015","unstructured":"Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF (2015) Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Association of baseline characteristics and early vision response with 2\u2011year vision outcomes in the comparison of AMD Treatments Trials (CATT). Ophthalmology 122(12):2523\u20132531","journal-title":"Ophthalmology"},{"issue":"5","key":"308_CR26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00347-014-3137-6","volume":"112","author":"M Ziegler","year":"2015","unstructured":"Ziegler M, Heimes B, Book B, Dietzel M, Zeimer M, Spital G, Gutfleisch M, Pauleikhoff D, Lommatzsch A (2015) Therapiewechsel von Ranibuzumab zu Aflibercept bei rezidivierender oder persistierender exudativer AMD. Ophthalmologe 112(5):435\u2013443","journal-title":"Ophthalmologe"},{"issue":"15","key":"308_CR27","doi-asserted-by":"publisher","first-page":"01421","DOI":"10.1016\/j.ophtha.2015.11.030.","volume":"S0161-6420","author":"N Shah","year":"2016","unstructured":"Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E (2016) Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology S0161-6420(15):01421\u201301429. doi:10.1016\/j.ophtha.2015.11.030","journal-title":"Ophthalmology"},{"issue":"15","key":"308_CR28","doi-asserted-by":"publisher","first-page":"01424","DOI":"10.1016\/j.ophtha.2015.12.002.","volume":"S0161-6420","author":"S Sharma","year":"2016","unstructured":"Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ (2016) Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-related\u00a0Macular Degeneration Treatments Trials. Ophthalmology S0161-6420(15):01424\u201301424. doi:10.1016\/j.ophtha.2015.12.002","journal-title":"Ophthalmology"},{"issue":"10","key":"308_CR29","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1167\/iovs.12-10580","volume":"53","author":"FB Sallo","year":"2012","unstructured":"Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UE, Clemons TE, Gillies MC, Pauleikhoff D, Rubin GS, Chew EY, Bird AC, MacTel Study Group (2012) \u201cEn face\u201d OCT imaging of the IS\/OS junction line in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 53(10):6145\u20136152","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0308-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-016-0308-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0308-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-016-0308-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:30:49Z","timestamp":1498311049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-016-0308-7"}},"subtitle":["K\u00f6nnen spezifische Charakteristika im SD-\ufeffOCT weiterhelfen?"],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1007\/s00347-016-0308-7","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}